OncLive® On Air

S17 Ep24: Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

S17 Ep22: Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD

S17 Ep23: FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MD

S17 Ep20: Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD

Biomarker-directed strategies are fundamentally transforming GI oncology, shifting the treatment paradigm from one-size-fits-all approaches to molecularly defined precision medicine. Dr. Pishvaian highlights the necessity of identifying specific genetic alterations—such as MSI-high, NTRK fusions, HER2, CLAUDIN18.2, and...

S17 Ep19: Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

S17 Ep18: Metastatic Bladder Cancer 2026 UPDATE

S17 Ep16: Show Me the Data®: From Mutation to Action—KRAS as a Therapeutic Target in PDAC

S17 Ep15: FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD

S17 Ep14: Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD

Relapsed small cell lung cancer treatment has shifted significantly with the FDA approval of tarlatamab, a DLL3-targeting T-cell engager that now serves as the second-line standard of care. Despite this progress, first-line management remains anchored in platinum-based chemotherapy and immunotherapy due to a lack of pr...

S17 Ep13: Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer

S17 Ep11: Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

S17 Ep9: Medical Crossfire®: Optimizing ESR1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

S17 Ep17: Localized Bladder Cancer 2026 UPDATE

S17 Ep8: From Molecular Insights to Clinical Impact: Translating the Latest Advances in Menin Inhibitors Into Practice

S17 Ep7: RAS/MAP Kinase Pathway Targeting Makes Strides in Gynecologic Cancer Management: With Ursula A. Matulonis, MD; and Elizabeth H. Stover, MD, PhD

S17 Ep6: Medical Crossfire®: Advancing Personalized Care in TNBC—Integrating Biomarkers, Clinical Evidence, and Emerging Therapies

S17 Ep5: Medical Crossfire® Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

S17 Ep4: Show Me the Data: Translating Clinical and Practice-Based Evidence on Oral SERDs Into Everyday Care for HR+/HER2– Metastatic Breast Cancer

Managing HR-positive HER2-negative metastatic breast cancer requires precise, biomarker-driven treatment sequencing based on evolving clinical evidence. NGS testing at initial diagnosis is essential for identifying PIK3CA mutations, which inform future therapeutic choices and metabolic management. As ESR1 mutations fre...

S17 Ep3: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2– Breast Cancer

S17 Ep2: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting